nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—ABCB1—Parkinson's disease	0.5	1	CbGaD
Sirolimus—MTOR—forelimb—Parkinson's disease	0.0141	0.1	CbGeAlD
Sirolimus—EIF4E—embryo—Parkinson's disease	0.00933	0.0664	CbGeAlD
Sirolimus—EIF4E—forebrain—Parkinson's disease	0.00825	0.0587	CbGeAlD
Sirolimus—EIF4E—cardiovascular system—Parkinson's disease	0.00698	0.0497	CbGeAlD
Sirolimus—MTOR—hindbrain—Parkinson's disease	0.00577	0.0411	CbGeAlD
Sirolimus—EIF4E—head—Parkinson's disease	0.00473	0.0336	CbGeAlD
Sirolimus—EIF4E—nervous system—Parkinson's disease	0.00448	0.0319	CbGeAlD
Sirolimus—SLC47A1—hindbrain—Parkinson's disease	0.00446	0.0318	CbGeAlD
Sirolimus—EIF4E—central nervous system—Parkinson's disease	0.00431	0.0307	CbGeAlD
Sirolimus—FGF2—medulla oblongata—Parkinson's disease	0.00364	0.0259	CbGeAlD
Sirolimus—MTOR—embryo—Parkinson's disease	0.00361	0.0257	CbGeAlD
Sirolimus—EIF4E—brain—Parkinson's disease	0.00342	0.0244	CbGeAlD
Sirolimus—FGF2—midbrain—Parkinson's disease	0.00332	0.0236	CbGeAlD
Sirolimus—MTOR—brainstem—Parkinson's disease	0.00331	0.0235	CbGeAlD
Sirolimus—FGF2—spinal cord—Parkinson's disease	0.00324	0.0231	CbGeAlD
Sirolimus—MTOR—forebrain—Parkinson's disease	0.00319	0.0227	CbGeAlD
Sirolimus—FKBP1A—forebrain—Parkinson's disease	0.00287	0.0204	CbGeAlD
Sirolimus—MTOR—cardiovascular system—Parkinson's disease	0.0027	0.0192	CbGeAlD
Sirolimus—FGF2—cerebellum—Parkinson's disease	0.00257	0.0183	CbGeAlD
Sirolimus—SLC47A1—brainstem—Parkinson's disease	0.00256	0.0182	CbGeAlD
Sirolimus—FKBP1A—cardiovascular system—Parkinson's disease	0.00243	0.0173	CbGeAlD
Sirolimus—FGF2—brain—Parkinson's disease	0.00209	0.0149	CbGeAlD
Sirolimus—FKBP1A—medulla oblongata—Parkinson's disease	0.00208	0.0148	CbGeAlD
Sirolimus—MTOR—spinal cord—Parkinson's disease	0.00206	0.0146	CbGeAlD
Sirolimus—Temsirolimus—CYP2D6—Parkinson's disease	0.00191	0.427	CrCbGaD
Sirolimus—FKBP1A—midbrain—Parkinson's disease	0.0019	0.0135	CbGeAlD
Sirolimus—FKBP1A—spinal cord—Parkinson's disease	0.00185	0.0132	CbGeAlD
Sirolimus—MTOR—head—Parkinson's disease	0.00183	0.013	CbGeAlD
Sirolimus—SLC47A1—medulla oblongata—Parkinson's disease	0.00178	0.0127	CbGeAlD
Sirolimus—MTOR—nervous system—Parkinson's disease	0.00173	0.0123	CbGeAlD
Sirolimus—MTOR—central nervous system—Parkinson's disease	0.00167	0.0119	CbGeAlD
Sirolimus—FKBP1A—head—Parkinson's disease	0.00164	0.0117	CbGeAlD
Sirolimus—MTOR—cerebellum—Parkinson's disease	0.00163	0.0116	CbGeAlD
Sirolimus—SLC47A1—spinal cord—Parkinson's disease	0.00159	0.0113	CbGeAlD
Sirolimus—FKBP1A—nervous system—Parkinson's disease	0.00156	0.0111	CbGeAlD
Sirolimus—FKBP1A—central nervous system—Parkinson's disease	0.0015	0.0107	CbGeAlD
Sirolimus—FKBP1A—cerebellum—Parkinson's disease	0.00147	0.0104	CbGeAlD
Sirolimus—SLC47A1—head—Parkinson's disease	0.00141	0.0101	CbGeAlD
Sirolimus—Temsirolimus—ABCB1—Parkinson's disease	0.00136	0.305	CrCbGaD
Sirolimus—SLC47A1—nervous system—Parkinson's disease	0.00134	0.00953	CbGeAlD
Sirolimus—MTOR—brain—Parkinson's disease	0.00133	0.00943	CbGeAlD
Sirolimus—SLC47A1—central nervous system—Parkinson's disease	0.00129	0.00918	CbGeAlD
Sirolimus—SLC47A1—cerebellum—Parkinson's disease	0.00126	0.00897	CbGeAlD
Sirolimus—Tacrolimus—ABCB1—Parkinson's disease	0.0012	0.268	CrCbGaD
Sirolimus—FKBP1A—brain—Parkinson's disease	0.00119	0.00848	CbGeAlD
Sirolimus—SLC47A1—brain—Parkinson's disease	0.00102	0.00729	CbGeAlD
Sirolimus—ABCB1—embryo—Parkinson's disease	0.000751	0.00535	CbGeAlD
Sirolimus—ABCB1—forebrain—Parkinson's disease	0.000664	0.00473	CbGeAlD
Sirolimus—ABCB1—cardiovascular system—Parkinson's disease	0.000562	0.004	CbGeAlD
Sirolimus—CYP3A4—nervous system—Parkinson's disease	0.00051	0.00363	CbGeAlD
Sirolimus—CYP3A4—central nervous system—Parkinson's disease	0.000491	0.00349	CbGeAlD
Sirolimus—ABCB1—medulla oblongata—Parkinson's disease	0.00048	0.00342	CbGeAlD
Sirolimus—ABCB1—midbrain—Parkinson's disease	0.000439	0.00312	CbGeAlD
Sirolimus—ABCB1—spinal cord—Parkinson's disease	0.000428	0.00305	CbGeAlD
Sirolimus—ABCB1—head—Parkinson's disease	0.00038	0.00271	CbGeAlD
Sirolimus—ABCB1—nervous system—Parkinson's disease	0.000361	0.00257	CbGeAlD
Sirolimus—ABCB1—central nervous system—Parkinson's disease	0.000347	0.00247	CbGeAlD
Sirolimus—ABCB1—cerebellum—Parkinson's disease	0.000339	0.00241	CbGeAlD
Sirolimus—ABCB1—brain—Parkinson's disease	0.000276	0.00196	CbGeAlD
Sirolimus—FGF2—Signaling Pathways—ADORA2A—Parkinson's disease	6.21e-05	0.000175	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—IL6—Parkinson's disease	6.06e-05	0.000171	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—ABCB1—Parkinson's disease	6.05e-05	0.00017	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—NGF—Parkinson's disease	6.03e-05	0.00017	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—IL6—Parkinson's disease	6.03e-05	0.00017	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—HTR7—Parkinson's disease	6.01e-05	0.000169	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—DRD2—Parkinson's disease	6.01e-05	0.000169	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—MTHFR—Parkinson's disease	6e-05	0.000169	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—IL6—Parkinson's disease	6e-05	0.000169	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GSTA4—Parkinson's disease	5.99e-05	0.000169	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—MAPK8—Parkinson's disease	5.99e-05	0.000169	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—IL6—Parkinson's disease	5.97e-05	0.000168	CbGpPWpGaD
Sirolimus—FGF2—Immune System—ABL1—Parkinson's disease	5.93e-05	0.000167	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—GPX1—Parkinson's disease	5.92e-05	0.000167	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PDYN—Parkinson's disease	5.83e-05	0.000164	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—DDC—Parkinson's disease	5.82e-05	0.000164	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—SLC18A2—Parkinson's disease	5.77e-05	0.000162	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—HTR2A—Parkinson's disease	5.74e-05	0.000162	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GBA—Parkinson's disease	5.73e-05	0.000162	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—FBP1—Parkinson's disease	5.73e-05	0.000162	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—DBH—Parkinson's disease	5.73e-05	0.000162	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—INSR—Parkinson's disease	5.73e-05	0.000161	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—TNF—Parkinson's disease	5.71e-05	0.000161	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—MCCC1—Parkinson's disease	5.71e-05	0.000161	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ND3—Parkinson's disease	5.71e-05	0.000161	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—IL6—Parkinson's disease	5.62e-05	0.000158	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—IL6—Parkinson's disease	5.62e-05	0.000158	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—Parkinson's disease	5.62e-05	0.000158	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—APOE—Parkinson's disease	5.59e-05	0.000157	CbGpPWpGaD
Sirolimus—FGF2—Immune System—HGF—Parkinson's disease	5.58e-05	0.000157	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—IL6—Parkinson's disease	5.56e-05	0.000157	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—IL6—Parkinson's disease	5.52e-05	0.000155	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GSTA4—Parkinson's disease	5.5e-05	0.000155	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—IL6—Parkinson's disease	5.49e-05	0.000155	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—GFAP—Parkinson's disease	5.48e-05	0.000154	CbGpPWpGaD
Sirolimus—CYP3A4—Biological oxidations—COMT—Parkinson's disease	5.42e-05	0.000153	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—GRM5—Parkinson's disease	5.42e-05	0.000153	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—FGB—Parkinson's disease	5.41e-05	0.000152	CbGpPWpGaD
Sirolimus—CYP3A4—Biological oxidations—GSTP1—Parkinson's disease	5.4e-05	0.000152	CbGpPWpGaD
Sirolimus—MTOR—Immune System—ADRBK1—Parkinson's disease	5.4e-05	0.000152	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PLA2G6—Parkinson's disease	5.39e-05	0.000152	CbGpPWpGaD
Sirolimus—CYP3A4—Biological oxidations—MAOA—Parkinson's disease	5.39e-05	0.000152	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HTR1A—Parkinson's disease	5.38e-05	0.000152	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—TALDO1—Parkinson's disease	5.37e-05	0.000151	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—OMD—Parkinson's disease	5.37e-05	0.000151	CbGpPWpGaD
Sirolimus—CYP3A4—Metapathway biotransformation—COMT—Parkinson's disease	5.35e-05	0.000151	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—MAOB—Parkinson's disease	5.34e-05	0.00015	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—APOE—Parkinson's disease	5.34e-05	0.00015	CbGpPWpGaD
Sirolimus—CYP3A4—Metapathway biotransformation—GSTP1—Parkinson's disease	5.33e-05	0.00015	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—CP—Parkinson's disease	5.31e-05	0.000149	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TAC1—Parkinson's disease	5.3e-05	0.000149	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—IL1B—Parkinson's disease	5.26e-05	0.000148	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—DRD1—Parkinson's disease	5.2e-05	0.000146	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—IL6—Parkinson's disease	5.15e-05	0.000145	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—NDUFB11—Parkinson's disease	5.09e-05	0.000143	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	5.08e-05	0.000143	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IGF2—Parkinson's disease	5.04e-05	0.000142	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—DRD3—Parkinson's disease	5.04e-05	0.000142	CbGpPWpGaD
Sirolimus—MTOR—Disease—ADRBK1—Parkinson's disease	4.98e-05	0.00014	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—Parkinson's disease	4.97e-05	0.00014	CbGpPWpGaD
Sirolimus—CYP3A4—Biological oxidations—GSTM1—Parkinson's disease	4.96e-05	0.00014	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PLA2G6—Parkinson's disease	4.95e-05	0.000139	CbGpPWpGaD
Sirolimus—MTOR—Disease—HSPA1A—Parkinson's disease	4.95e-05	0.000139	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—MAOB—Parkinson's disease	4.9e-05	0.000138	CbGpPWpGaD
Sirolimus—CYP3A4—Metapathway biotransformation—GSTM1—Parkinson's disease	4.89e-05	0.000138	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IGF1R—Parkinson's disease	4.87e-05	0.000137	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GCH1—Parkinson's disease	4.86e-05	0.000137	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—MAPK8—Parkinson's disease	4.82e-05	0.000136	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—EDN1—Parkinson's disease	4.81e-05	0.000136	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—INS—Parkinson's disease	4.77e-05	0.000134	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—FGF20—Parkinson's disease	4.75e-05	0.000134	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ADRBK1—Parkinson's disease	4.7e-05	0.000132	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ADORA2A—Parkinson's disease	4.61e-05	0.00013	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—MAPK8—Parkinson's disease	4.6e-05	0.00013	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—INS—Parkinson's disease	4.56e-05	0.000128	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—DRD2—Parkinson's disease	4.55e-05	0.000128	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HTR7—Parkinson's disease	4.55e-05	0.000128	CbGpPWpGaD
Sirolimus—FGF2—Disease—MTHFR—Parkinson's disease	4.55e-05	0.000128	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—NGF—Parkinson's disease	4.42e-05	0.000125	CbGpPWpGaD
Sirolimus—MTOR—Immune System—ABL1—Parkinson's disease	4.4e-05	0.000124	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—DBH—Parkinson's disease	4.33e-05	0.000122	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—FBP1—Parkinson's disease	4.33e-05	0.000122	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GBA—Parkinson's disease	4.33e-05	0.000122	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—INSR—Parkinson's disease	4.25e-05	0.00012	CbGpPWpGaD
Sirolimus—FGF2—Disease—APOE—Parkinson's disease	4.24e-05	0.000119	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—HTR2A—Parkinson's disease	4.21e-05	0.000119	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—DDC—Parkinson's disease	4.21e-05	0.000119	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HGF—Parkinson's disease	4.14e-05	0.000117	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—TNF—Parkinson's disease	4.13e-05	0.000116	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—IL6—Parkinson's disease	4.08e-05	0.000115	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—FGB—Parkinson's disease	4.02e-05	0.000113	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HTR1A—Parkinson's disease	4e-05	0.000113	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GSTA4—Parkinson's disease	3.97e-05	0.000112	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CYP2D6—Parkinson's disease	3.97e-05	0.000112	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TAC1—Parkinson's disease	3.94e-05	0.000111	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—APOE—Parkinson's disease	3.91e-05	0.00011	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CTGF—Parkinson's disease	3.9e-05	0.00011	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—Parkinson's disease	3.88e-05	0.000109	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—DRD1—Parkinson's disease	3.86e-05	0.000109	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—IL6—Parkinson's disease	3.83e-05	0.000108	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IGF2—Parkinson's disease	3.82e-05	0.000108	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—SLC6A3—Parkinson's disease	3.78e-05	0.000106	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—DRD3—Parkinson's disease	3.74e-05	0.000105	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IGF1R—Parkinson's disease	3.69e-05	0.000104	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—EDN1—Parkinson's disease	3.65e-05	0.000103	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CYP2D6—Parkinson's disease	3.64e-05	0.000103	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—CYCS—Parkinson's disease	3.63e-05	0.000102	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CYP2E1—Parkinson's disease	3.63e-05	0.000102	CbGpPWpGaD
Sirolimus—FGF2—Disease—INS—Parkinson's disease	3.62e-05	0.000102	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—NQO1—Parkinson's disease	3.59e-05	0.000101	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PLA2G6—Parkinson's disease	3.58e-05	0.000101	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CTGF—Parkinson's disease	3.58e-05	0.000101	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—Parkinson's disease	3.56e-05	0.0001	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—MAOB—Parkinson's disease	3.54e-05	9.98e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—TH—Parkinson's disease	3.54e-05	9.96e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ND3—Parkinson's disease	3.52e-05	9.91e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—MCCC1—Parkinson's disease	3.52e-05	9.91e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ADRBK1—Parkinson's disease	3.49e-05	9.83e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—MAPK8—Parkinson's disease	3.42e-05	9.62e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CYCS—Parkinson's disease	3.4e-05	9.57e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CASP3—Parkinson's disease	3.39e-05	9.56e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HTR7—Parkinson's disease	3.38e-05	9.52e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—DRD2—Parkinson's disease	3.38e-05	9.52e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—MTHFR—Parkinson's disease	3.38e-05	9.51e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NGF—Parkinson's disease	3.35e-05	9.44e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—INS—Parkinson's disease	3.34e-05	9.42e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CYP2E1—Parkinson's disease	3.33e-05	9.38e-05	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—IL6—Parkinson's disease	3.33e-05	9.38e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—OMD—Parkinson's disease	3.31e-05	9.32e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—TALDO1—Parkinson's disease	3.31e-05	9.32e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—NQO1—Parkinson's disease	3.29e-05	9.28e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—TH—Parkinson's disease	3.25e-05	9.14e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HTR2A—Parkinson's disease	3.19e-05	8.98e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—DDC—Parkinson's disease	3.18e-05	8.95e-05	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—HMOX1—Parkinson's disease	3.16e-05	8.89e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—APOE—Parkinson's disease	3.14e-05	8.85e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NDUFB11—Parkinson's disease	3.14e-05	8.83e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MAPK8—Parkinson's disease	3.12e-05	8.78e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CYCS—Parkinson's disease	3.12e-05	8.78e-05	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—IL6—Parkinson's disease	3.08e-05	8.68e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—COMT—Parkinson's disease	3.01e-05	8.47e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GSTA4—Parkinson's disease	3e-05	8.45e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GSTP1—Parkinson's disease	2.99e-05	8.43e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GCH1—Parkinson's disease	2.99e-05	8.42e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—MAOA—Parkinson's disease	2.99e-05	8.41e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—APOE—Parkinson's disease	2.97e-05	8.35e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—HMOX1—Parkinson's disease	2.95e-05	8.32e-05	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—IL6—Parkinson's disease	2.94e-05	8.28e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL1B—Parkinson's disease	2.92e-05	8.24e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ABCB1—Parkinson's disease	2.83e-05	7.98e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IGF2—Parkinson's disease	2.83e-05	7.98e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Parkinson's disease	2.82e-05	7.94e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—COMT—Parkinson's disease	2.76e-05	7.78e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GSTM1—Parkinson's disease	2.75e-05	7.75e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GSTP1—Parkinson's disease	2.75e-05	7.74e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—MAOA—Parkinson's disease	2.74e-05	7.72e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IGF1R—Parkinson's disease	2.74e-05	7.71e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—HMOX1—Parkinson's disease	2.71e-05	7.63e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—EDN1—Parkinson's disease	2.71e-05	7.62e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PLA2G6—Parkinson's disease	2.7e-05	7.61e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—INS—Parkinson's disease	2.68e-05	7.56e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—MAPK8—Parkinson's disease	2.68e-05	7.55e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—MAOB—Parkinson's disease	2.67e-05	7.53e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—DBH—Parkinson's disease	2.67e-05	7.51e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—FBP1—Parkinson's disease	2.67e-05	7.51e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GBA—Parkinson's disease	2.67e-05	7.51e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GPX1—Parkinson's disease	2.63e-05	7.42e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYP2D6—Parkinson's disease	2.63e-05	7.42e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ABCB1—Parkinson's disease	2.6e-05	7.33e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CTGF—Parkinson's disease	2.58e-05	7.28e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—INS—Parkinson's disease	2.53e-05	7.14e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GSTM1—Parkinson's disease	2.52e-05	7.11e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CASP3—Parkinson's disease	2.49e-05	7.01e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NGF—Parkinson's disease	2.49e-05	7e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—MTHFR—Parkinson's disease	2.43e-05	6.85e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GPX1—Parkinson's disease	2.42e-05	6.81e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYP2E1—Parkinson's disease	2.41e-05	6.78e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—NQO1—Parkinson's disease	2.38e-05	6.71e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HTR2A—Parkinson's disease	2.37e-05	6.67e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—TH—Parkinson's disease	2.35e-05	6.61e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MAPK8—Parkinson's disease	2.29e-05	6.44e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—APOE—Parkinson's disease	2.26e-05	6.38e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYCS—Parkinson's disease	2.25e-05	6.35e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—MTHFR—Parkinson's disease	2.23e-05	6.28e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—APOE—Parkinson's disease	2.2e-05	6.2e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—IL6—Parkinson's disease	2.18e-05	6.14e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL1B—Parkinson's disease	2.17e-05	6.11e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—IL6—Parkinson's disease	2.09e-05	5.88e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—APOE—Parkinson's disease	2.08e-05	5.85e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—COMT—Parkinson's disease	2e-05	5.62e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IL6—Parkinson's disease	1.99e-05	5.61e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—MAPK8—Parkinson's disease	1.99e-05	5.6e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP2D6—Parkinson's disease	1.99e-05	5.6e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GSTP1—Parkinson's disease	1.99e-05	5.59e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—MAOA—Parkinson's disease	1.98e-05	5.58e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—HMOX1—Parkinson's disease	1.96e-05	5.52e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—DDC—Parkinson's disease	1.96e-05	5.51e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CTGF—Parkinson's disease	1.95e-05	5.49e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—INS—Parkinson's disease	1.93e-05	5.45e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CASP3—Parkinson's disease	1.89e-05	5.31e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—INS—Parkinson's disease	1.88e-05	5.3e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ABCB1—Parkinson's disease	1.88e-05	5.3e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTA4—Parkinson's disease	1.85e-05	5.2e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GSTM1—Parkinson's disease	1.83e-05	5.14e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP2E1—Parkinson's disease	1.82e-05	5.12e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—NQO1—Parkinson's disease	1.8e-05	5.06e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—INS—Parkinson's disease	1.77e-05	5e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—TH—Parkinson's disease	1.77e-05	4.99e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GPX1—Parkinson's disease	1.75e-05	4.92e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MAPK8—Parkinson's disease	1.73e-05	4.88e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL6—Parkinson's disease	1.71e-05	4.82e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYCS—Parkinson's disease	1.7e-05	4.79e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PLA2G6—Parkinson's disease	1.66e-05	4.69e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—MAOB—Parkinson's disease	1.65e-05	4.64e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—MTHFR—Parkinson's disease	1.61e-05	4.54e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—IL6—Parkinson's disease	1.58e-05	4.45e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—COMT—Parkinson's disease	1.51e-05	4.24e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—APOE—Parkinson's disease	1.5e-05	4.23e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GSTP1—Parkinson's disease	1.5e-05	4.22e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—MAOA—Parkinson's disease	1.5e-05	4.21e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—HMOX1—Parkinson's disease	1.48e-05	4.16e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IL6—Parkinson's disease	1.46e-05	4.11e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CASP3—Parkinson's disease	1.4e-05	3.94e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GSTM1—Parkinson's disease	1.38e-05	3.88e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GPX1—Parkinson's disease	1.32e-05	3.71e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MAPK8—Parkinson's disease	1.29e-05	3.62e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—INS—Parkinson's disease	1.28e-05	3.61e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL6—Parkinson's disease	1.27e-05	3.58e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP2D6—Parkinson's disease	1.22e-05	3.45e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—MTHFR—Parkinson's disease	1.22e-05	3.43e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CTGF—Parkinson's disease	1.2e-05	3.38e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—IL6—Parkinson's disease	1.17e-05	3.3e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—APOE—Parkinson's disease	1.13e-05	3.19e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP2E1—Parkinson's disease	1.12e-05	3.15e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL6—Parkinson's disease	1.11e-05	3.12e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NQO1—Parkinson's disease	1.11e-05	3.12e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—TH—Parkinson's disease	1.09e-05	3.07e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYCS—Parkinson's disease	1.05e-05	2.95e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—INS—Parkinson's disease	9.68e-06	2.73e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—COMT—Parkinson's disease	9.28e-06	2.61e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTP1—Parkinson's disease	9.23e-06	2.6e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—MAOA—Parkinson's disease	9.21e-06	2.59e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—HMOX1—Parkinson's disease	9.11e-06	2.56e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ABCB1—Parkinson's disease	8.74e-06	2.46e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTM1—Parkinson's disease	8.49e-06	2.39e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL6—Parkinson's disease	8.22e-06	2.31e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GPX1—Parkinson's disease	8.13e-06	2.29e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—MTHFR—Parkinson's disease	7.5e-06	2.11e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—APOE—Parkinson's disease	6.98e-06	1.97e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—INS—Parkinson's disease	5.96e-06	1.68e-05	CbGpPWpGaD
